Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer ; volume:2 ; number:1 ; day:15 ; month:5 ; year:2014 ; pages:1-14 ; date:12.2014
Journal for ImmunoTherapy of Cancer ; 2, Heft 1 (15.5.2014), 1-14, 12.2014
- Urheber
-
Ascierto, Paolo A.
- Beteiligte Personen und Organisationen
-
Munn, David H.
Palucka, Anna K.
Sondel, Paul M.
SpringerLink (Online service)
- DOI
-
10.1186/2051-1426-2-15
- URN
-
urn:nbn:de:1111-2016072656153
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ascierto, Paolo A.
- Munn, David H.
- Palucka, Anna K.
- Sondel, Paul M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
What have we learned from cancer immunotherapy in the last 3 years?
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Combination therapy: the next opportunity and challenge of medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016
Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021
The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014
What have we learned from cancer immunotherapy in the last 3 years?
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Combination therapy: the next opportunity and challenge of medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016
Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021
The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014
What have we learned from cancer immunotherapy in the last 3 years?
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Combination therapy: the next opportunity and challenge of medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016
Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021